Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual ...

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Information technology services firm Cognizant and transport and logistics firm A.P. Moller – Maersk are exploring investment opportunities in the Philippines, according to the Department of Trade and ...

Bracing for a federal funding drought and higher state costs for Medicare and Medicaid, Gov. Ned Lamont urged pharma ...

MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, its chief strategy officer and Alexion CEO Marc Dunoyer said in a meeting ...

Shares of the British-Swedish pharmaceutical titan AstraZeneca are trading 7% lower in London today as investors price in the acquisition of Alexion Pharmaceuticals for $39 billion. A deal, which is ...